- 10/18/2018
- eisai to present latest data on alzheimer’s disease / dementia pipeline at 11th clinical trials on alzheimer’s disease conference
- 10/17/2018
- eisai and purdue pharma announce positive topline results of sunrise 2, the second phase 3 pivotal study of lemborexant
- 10/12/2018
- new drug application for perampanel for adjunctive treatment of partial onset seizures accepted in china
- 09/05/2018
- eisai and merck & co., inc., kenilworth, n.j., u.s.a. announce china national medical products administration (nmpa) approval of lenvima® (lenvatinib) for treatment of unresectable hepatocellular carc
- 08/29/2018
- lenvima® (lenvatinib) capsules approved for first-line treatment of unresectable hepatocellular carcinoma (hcc) in south korea
- 08/28/2018
- long-term cardiovascular outcomes data for anti-obesity agent belviq® presented at the european society of cardiology and published in the new england journal of medicine
- 08/23/2018
- european commission grants marketing authorization for lenvima® (lenvatinib) as first-line treatment in adults with advanced or unresectable hepatocellular carcinoma
- 08/22/2018
- eisai china inc. awarded great suzhou best employer for second consecutive years
- 08/17/2018
- eisai and merck & co., inc., kenilworth, n.j., u.s.a. announce fda approval of lenvima® (lenvatinib) capsules for first-line treatment of unresectable hepatocellular carcinoma (hcc)
- 08/04/2018
- eisai (china) listed for the third consecutive year in china top 100 pharmaceutical companies
